Everolimus therapy for progressive adrenocortical cancer.

Everolimus therapy for progressive adrenocortical cancer.

Mostra altre versioni (1)

Patients with advanced adrenocortical carcinoma (ACC) have limited treatment options after failure of chemotherapy. Tumor IGF2 expression has been shown to be amplified in the majority of cases of ACC and autocrine/paracrine activation of the IGF receptor (IGF-R) is thought to play a major role in t...

Descrizione completa

Dettagli Bibliografici
Autori principali:	Fraenkel, M, Gueorguiev, M, Barak, D, Salmon, A, Grossman, AB, Gross, D
Natura:	Journal article
Lingua:	English
Pubblicazione:	2013

Documenti analoghi

Everolimus therapy for progressive adrenocortical cancer
di: Fraenkel, M, et al.
Pubblicazione: (2013)

Adrenocortical Cancer: A Therapeutic Approach with Everolimus (RAD001)
di: Gueorguiev, M, et al.
Pubblicazione: (2010)

Novel and evolving therapies in the treatment of malignant phaeochromocytoma: experience with the mTOR inhibitor everolimus (RAD001).
di: Druce, MR, et al.
Pubblicazione: (2009)

Preliminary report of the use of everolimus in a patient with progressive medullary thyroid carcinoma
di: Druce, M, et al.
Pubblicazione: (2012)

Preliminary report of the use of everolimus in a patient with progressive medullary thyroid carcinoma.
di: Druce, M, et al.
Pubblicazione: (2012)

Adrenocortical carcinoma: the range of appearances on CT and MRI.
di: Bharwani, N, et al.
Pubblicazione: (2011)

Preliminary Report of the Use of Everolimus in a Patient with Progressive Medullary Thyroid Carcinoma
di: Druce, M, et al.
Pubblicazione: (2010)

IGF2-induced hypoglycemia unresponsive to everolimus.
di: Korevaar, T, et al.
Pubblicazione: (2014)

Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
di: Chan, H, et al.
Pubblicazione: (2010)

ALTERED ADRENOCORTICAL-RESPONSE TO CRF STIMULATION IN OBESITY
di: Kopelman, P, et al.
Pubblicazione: (1987)

Response and Acquired Resistance to Everolimus in Anaplastic Thyroid Cancer
di: Van Allen, Eliezer M., et al.
Pubblicazione: (2017)

EVEROLIMUS PLUS OCTREOTIDE LAR IN PATIENTS WITH LUNG CARCINOIDS
di: Granberg, D, et al.
Pubblicazione: (2014)

Lack of modulation of the adrenocortical response to ACTH by an opioid peptide.
di: Howlett, T, et al.
Pubblicazione: (1991)

Combination of everolimus with sorafenib for solid renal tumors in Tsc2+/- mice is duperior to everolimus alone
di: Yang, J, et al.
Pubblicazione: (2017)

SERUM CORTISOL IS NOT AN ACCURATE PREDICTOR OF THE INTEGRITY OF THE HYPOTHALAMIC-PITUITARY-ADRENOCORTICAL AXIS - REPLY
di: Grossman, A
Pubblicazione: (1995)

Primary pigmented nodular adrenocortical dysplasia: a rare form of a rare disorder.
di: Jabbar, A, et al.
Pubblicazione: (1994)

Primary pigmented nodular adrenocortical disease
di: Ngow, Harris Abdullah, et al.
Pubblicazione: (2011)

Everolimus for renal angiomyolipoma in tuberous sclerosis.
di: Sooriakumaran, P, et al.
Pubblicazione: (2013)

An update on adrenocortical cell lines of human origin
di: Sigala, Sandra, et al.
Pubblicazione: (2022)

Childhood adrenocortical carcinoma as a sentinel cancer for detecting families with germline TP53 mutations
di: Choong, S.S., et al.
Pubblicazione: (2012)

Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5α-reductase, explaining the need for personalized glucocorticoid and androgen replacement.
di: Chortis, V, et al.
Pubblicazione: (2013)

Assessment of serum-free cortisol levels in patients with adrenocortical carcinoma treated with mitotane: a pilot study.
di: Alexandraki, K, et al.
Pubblicazione: (2010)

Clinical features, diagnosis, treatment and molecular studies in paediatric Cushing's syndrome due to primary nodular adrenocortical hyperplasia.
di: Storr, H, et al.
Pubblicazione: (2004)

Effect of Everolimus plus Octreotide LAR in Patients With Advanced Lung Neuroendocrine Tumours - Analysis From RADIANT-2
di: Fazio, N, et al.
Pubblicazione: (2011)

Nicotinamide Nucleotide Transhydrogenase as a novel treatment target in adrenocortical carcinoma
di: Chortis, Vasileios, et al.
Pubblicazione: (2018)

Adrenocortical function in active and treated tuberculosis in chest clinic Ipoh Hospital
di: A.Muthukumaru, Umadevi
Pubblicazione: (2002)

Gene therapy and cancer research progress /
di: Lewis, Jessica L.
Pubblicazione: (2008)

Phase-3 randomized trial of everolimus (RAD001) vs. placebo in advanced pancreatic NET (RADIANT-3)
di: Chambers, J, et al.
Pubblicazione: (2010)

The effects of a met-enkephalin analogue on ACTH, beta-LPH, beta-endorphin and MET-enkephalin in patients with adrenocortical disease.
di: Gaillard, R, et al.
Pubblicazione: (1981)

Everolimus-eluting stents or bypass surgery for left main coronary artery disease.
di: Stone, GW, et al.
Pubblicazione: (2016)

Increased 5 alpha-reductase activity and adrenocortical drive in women with polycystic ovary syndrome.
di: Vassiliadi, D, et al.
Pubblicazione: (2009)

The addition of the mTORr inhibitor, Everolimus, to consolidation therapy in acute myeloid leukaemia: experience from the UK NCRI AML17 trial
di: Burnett, AK, et al.
Pubblicazione: (2018)

A common polymorphism in the retinoic acid pathway modifies adrenocortical carcinoma age-dependent incidence
di: Surakhy, M, et al.
Pubblicazione: (2020)

Extracellular vesicles in pancreatic cancer progression and therapies
di: Chang, C-H, et al.
Pubblicazione: (2021)

Gene therapy in the treatment of cancer : progress and prospects /
di: Huber, Brian E., et al.
Pubblicazione: (1998)

The role of fibroblasts in cancer progression, therapy resistance and field cancerization
di: Chan, Jeremy Soon Kiat
Pubblicazione: (2017)

Case report: A giant hemorrhagic adrenocortical carcinoma causing cardiorespiratory embarrassment
di: Yeap, Boon Tat, et al.
Pubblicazione: (2021)

Neural responses to partner rejection predict adrenocortical reactivity in adolescent romantic couples
di: Ha, T, et al.
Pubblicazione: (2015)

Medullary thyroid cancer: molecular biology and novel molecular therapies.
di: Cakir, M, et al.
Pubblicazione: (2009)

Pituitary gland and beta-catenin signaling: from ontogeny to oncogenesis.
di: Gueorguiev, M, et al.
Pubblicazione: (2009)